01 — At a Glance
The Generic Pharma Darling That Wall Street Forgot to Notice
- 52-Week High / Low₹271 / ₹156
- Q3 FY26 Revenue₹754 Cr
- Q3 FY26 PAT₹113.7 Cr
- Q3 EPS (₹)₹2.50
- 9M FY26 Revenue₹2,094.8 Cr
- 9M FY26 EPS (₹)₹6.0
- Debt / Equity0.12x
- Current Ratio5.18x
- Cash on Books₹824 Cr
- Book Value₹59.3
The Plot Summary: Marksans Pharma just delivered its strongest-ever quarterly revenue of ₹754 crore, up 10.6% YoY. EBITDA margin expanded to 21.3% (up 217 bps YoY). The US business grew 16.9% with “robust order book” worth $220 million waiting to commercialize. The UK stopped crying about pricing pressure and finally “stabilized.” And the company is strategically positioning itself as a global player by expanding into Europe and Canada. Yet the stock is down 12.4% in three months. Because apparently, the market rewards visibility with indifference. Classic.
02 — Introduction
Who Are These Guys, Anyway?
Marksans Pharma. Founded in 1992. Listed in 1994. Promotes: Mark and Sandra Saldanha, with over 30 years of pharma experience and a combined stake of 43.87%. You’ve never heard of them because they don’t sell medicines to you — they sell tablets, capsules, liquids, and ointments to retailers. Target, Walmart, Walgreens in the US. Tesco, Asda, Morrisons in the UK. Woolworths and Coles in Australia. Your cough syrup? Probably made by them. Your kid’s paracetamol? Same house. Your neighbour’s pain management gel? Sitting at a Marksans facility right now.
The company operates in what the market calls the “unsexy” generic pharmaceutical space: making products for private labels and branded players in regulated markets. No blockbuster drugs. No biotech buzz. No Tesla story. Just steady, boring, incredibly profitable manufacturing for blue-chip retailers worldwide.
In Q3 FY26, they delivered ₹754 crore in revenue — their highest-ever quarterly number. They’ve filed 25+ ANDAs/MAs awaiting approvals across geographies. They’re expanding into Europe and Canada. They’re ramping up a ₹800 crore capacity at their recently acquired Teva facility in Goa. And the stock has gone sideways. Because sometimes the best businesses are the least flashy.
Concall Reality Check (Feb 2026): “We are literally filing 4 or 5 products every month in the UK.” — Marksans Management. That’s 50+ products annually. Most pharma companies dream of that cadence. Marksans does it before breakfast.
03 — Business Model: Generic Pills for Giant Retailers
The Unsexy Machine That Prints Cash
Revenue mix: 74% OTC (painkillers, cough syrups, vitamins), 26% prescription drugs. Geography mix (9M FY26): US/North America 53.8%, UK/Europe 33.8%, Australia/NZ 8.6%, Rest of World 3.8%. The company has four manufacturing plants — two in India (Goa), one in the US (Farmingdale, NY), one in the UK (Southport). All are FDA-accredited. Combined capacity: 26 billion units per year, including tablets, capsules, liquids, ointments, and sachets.
How they make money: Major retailers (Target, Walmart, Walgreens, Tesco, Asda) place bulk orders for private-label OTC medicines. Marksans manufactures, bottles, labels, and ships. Margin: typically 55-58% on gross profit, EBITDA margin in the 19-21% band. The business is contract manufacturing with a dash of quality certification. No sales team. No direct-to-consumer overhead. Just efficiency, volume, and regulatory compliance.
Why this matters: Private-label OTC is sticky. Retailers don’t change suppliers easily. Marksans has 300+ approved SKUs across global markets and 25+ new ANDAs/MAs filed. Pipeline execution is a scorecard. In Q3 alone, they commercialized 55-60 SKUs. That’s market leadership in the invisible pharma space.
OTC Mix74%Private Label Heavy
Rx Mix26%Specialty Focus
Geographic Diversity4 Continents50+ Countries
SKU Portfolio300+Regulatory Approved
Capital Intensity: Low. The Teva acquisition in Goa cost ₹129.4 crore in capex for 9M FY26. That single facility is now contributing ₹560-600 crore annually with a path to ₹800 crore. ROI on that facility will be recovered in under 3 years. Boring efficiency at its finest.
💬 How many tablets have you unknowingly swallowed that were made by Marksans Pharma? And does knowing this change your life at all?
04 — Financials Overview
Q3 FY26: The Numbers That Matter
